Mednax Company Profile (NYSE:MD)

About Mednax (NYSE:MD)

MEDNAX, Inc. is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company's national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications. As of December 31, 2016, the Company had over 1,390 affiliated physicians providing anesthesia care to patients in connection with surgical and other procedures, as well as pain management. As of December 31, 2016, the Company had 270 affiliated physicians providing maternal-fetal and obstetrical medical care to expectant mothers experiencing complicated pregnancies primarily in areas where its affiliated neonatal physicians practice.

Industry, Sector and Symbol:

Sector: Medical
Industry: Healthcare Facilities & Services
Sub-Industry: Health Care Services
Symbol: NYSE:MD
CUSIP: 58502B10
Web: www.mednax.com

Capitalization:

Market Cap: $3.94581 billion
Outstanding Shares: 93,569,000

Average Prices:

50 Day Moving Avg: $43.06
200 Day Moving Avg: $52.91
52 Week Range: $40.78 - $72.13

P/E:

Trailing P/E Ratio: 13.47
Foreward P/E Ratio: 12.74
P/E Growth: 0.90

Sales & Book Value:

Annual Revenue: $3.34 billion
Price / Sales: 1.18
Book Value: $30.79 per share
Price / Book: 1.37

Profitability:

EBITDA: $628.4 million
Net Margins: 8.78%
Return on Equity: 11.89%
Return on Assets: 6.10%

Debt:

Debt-to-Equity Ratio: 0.62%
Current Ratio: 1.59%
Quick Ratio: 1.59%

Misc:

Average Volume: 1.25 million shs.
Beta: 0.37
Short Ratio: 8.38

Frequently Asked Questions for Mednax (NYSE:MD)

What is Mednax's stock symbol?

Mednax trades on the New York Stock Exchange (NYSE) under the ticker symbol "MD."

How were Mednax's earnings last quarter?

Mednax, Inc (NYSE:MD) announced its earnings results on Friday, July, 28th. The company reported $0.85 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.81 by $0.04. The firm earned $843 million during the quarter, compared to analyst estimates of $849.49 million. Mednax had a net margin of 8.78% and a return on equity of 11.89%. The company's revenue for the quarter was up 9.2% compared to the same quarter last year. During the same period in the prior year, the business earned $1.03 EPS. View Mednax's Earnings History.

When will Mednax make its next earnings announcement?

Mednax is scheduled to release their next quarterly earnings announcement on Wednesday, October, 25th 2017. View Earnings Estimates for Mednax.

What guidance has Mednax issued on next quarter's earnings?

Mednax issued an update on its third quarter earnings guidance on Friday, July, 28th. The company provided EPS guidance of $0.83-0.88 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.98.

Where is Mednax's stock going? Where will Mednax's stock price be in 2017?

11 equities research analysts have issued 1-year price targets for Mednax's shares. Their predictions range from $46.00 to $69.00. On average, they expect Mednax's stock price to reach $55.44 in the next twelve months. View Analyst Ratings for Mednax.

What are analysts saying about Mednax stock?

Here are some recent quotes from research analysts about Mednax stock:

1. According to Zacks Investment Research, "Mednax, Inc., formerly Pediatrix Medical Group, Inc. is a healthcare services company that focuses on physician services for newborn, maternal-fetal, pediatric subspecialty and anesthesia care. The company ,through its subsidiaries, provides these services in the United States and Puerto Rico. In addition, MEDNAX engages in clinical research, monitoring clinical outcomes, and implementing clinical initiatives. " (10/11/2017)
2. Jefferies Group LLC analysts commented, "Following MD's 5% EPS miss in Q4, we believe our Hold thesis from our December downgrade still holds and would expect the stock to give up some of its premium valuation pending improved earnings visibility. Broader birth trends remain subdued, MD faces its toughest comp of the year in Q1-17, and the company's deal flow remains relatively moderate, leading us to believe that the achievability of Q1 guidance (following 3 consecutive EPS misses) remains uncertain." (2/8/2017)

Who are some of Mednax's key competitors?

Some companies that are related to Mednax include NMC Health PLC (NMC), HealthSouth Corporation (HLS), Acadia Healthcare Company (ACHC), Chemed Corp. (CHE), Select Medical Holdings Corporation (SEM), Udg Healthcare PLC (UDG), LifePoint Health (LPNT), HMS Holdings Corp (HMSY), Tenet Healthcare Corporation (THC), China Cord Blood Corporation (CO), HealthStream (HSTM), Community Health Systems (CYH), Kindred Healthcare (KND), Georgia Healthcare Group PLC (GHG), American Renal Associates Holdings (ARA), Cambian Group PLC (CMBN), Concord Medical Services Holdings Limited (CCM) and Nobilis Health Corp (HLTH).

Who are Mednax's key executives?

Mednax's management team includes the folowing people:

Cesar L. Alvarez, Chairman of the Board
Joseph M. Calabro, President, Chief Operating Officer
Roger J. Medel M.D., Chief Executive Officer, Director
Vivian Lopez-Blanco, Chief Financial Officer, Treasurer
David A. Clark, President - MEDNAX National Medical Group Division
John C. Pepia, Senior Vice President, Chief Accounting Officer
Dominic J. Andreano, Senior Vice President, General Counsel, Secretary
Manuel Kadre, Lead Independent Director
Karey D. Barker, Independent Director
Waldemar A. Carlo M.D., Independent Director

Who owns Mednax stock?

Mednax's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Tandem Investment Advisors Inc. (0.02%). Company insiders that own Mednax stock include Dominic J Andreano, Enrique Sosa, John C Pepia, Joseph M Calabro, Karl B Wagner, Manuel Kadre, Md Carlo A Waldemar, Md Pascal J Goldschmidt, Michael D Stanley, Paul G Gabos and Vivian Lopez-Blanco. View Institutional Ownership Trends for Mednax.

Who sold Mednax stock? Who is selling Mednax stock?

Mednax's stock was sold by a variety of institutional investors in the last quarter, including Tandem Investment Advisors Inc.. Company insiders that have sold Mednax stock in the last year include Dominic J Andreano, Enrique Sosa, John C Pepia, Joseph M Calabro, Md Carlo A Waldemar, Md Pascal J Goldschmidt, Paul G Gabos and Vivian Lopez-Blanco. View Insider Buying and Selling for Mednax.

How do I buy Mednax stock?

Shares of Mednax can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Mednax's stock price today?

One share of Mednax stock can currently be purchased for approximately $42.29.

MarketBeat Community Rating for Mednax (NYSE MD)

Community Ranking:		2.3 out of 5 ( )
Outperform Votes:		229 (Vote Outperform)
Underperform Votes:		270 (Vote Underperform)
Total Votes:		499

MarketBeat's community ratings are surveys of what our community members think about Mednax and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Consensus Ratings for Mednax (NYSE:MD) (How are Consensus Ratings Calculated?)

Ratings Breakdown:	1 Sell Rating, 8 Hold Ratings, 2 Buy Ratings
Consensus Rating:	Hold (Score: 2.09)
Consensus Price Target:	$55.44 (31.11% upside)

Consensus Price Target History for Mednax (NYSE:MD)

Analysts' Ratings History for Mednax (NYSE:MD)

Show:

Date	Firm	Action	Rating	Price Target	Impact on Share Price
10/16/2017	BMO Capital Markets	Initiated Coverage	Market Perform	$46.00	N/A
10/3/2017	Jefferies Group LLC	Reiterated Rating	Hold	$46.00	Medium
9/17/2017	KeyCorp	Upgrade	Sector Weight -> Overweight	$51.00	Low
9/3/2017	Robert W. Baird	Reiterated Rating	Hold	$47.00	Medium
8/1/2017	Mizuho	Reiterated Rating	Neutral	$62.00 -> $48.00	Medium
6/22/2017	Stephens	Upgrade	Equal Weight -> Overweight	$55.00 -> $68.00	High
5/25/2017	Stifel Nicolaus	Lower Price Target	Hold	$65.00 -> $58.00	Low
5/4/2017	Bank of America Corporation	Downgrade	Buy -> Underperform		Low
3/10/2017	J P Morgan Chase & Co	Reiterated Rating	Overweight -> Neutral	$69.00	Low
12/9/2016	Goldman Sachs Group, Inc. (The)	Initiated Coverage	Neutral	$66.00	N/A
10/27/2016	Raymond James Financial, Inc.	Downgrade	Outperform -> Market Perform		N/A
8/17/2016	Citigroup Inc.	Lower Price Target	Neutral	$76.00 -> $72.00	N/A
3/14/2016	Piper Jaffray Companies	Reiterated Rating	Overweight	$76.00	N/A
3/7/2016	Susquehanna Bancshares Inc	Downgrade	Positive -> Neutral	$94.00 -> $70.00	N/A

(Data available from 10/17/2015 forward)

Earnings History for Mednax (NYSE:MD)

Earnings by Quarter for Mednax (NYSE:MD)

Earnings History by Quarter for Mednax (NYSE MD)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
10/25/2017		$0.87					N/A
7/28/2017	Q2 2017	$0.81	$0.85	$849.49 million	$843.00 million	View	N/A
5/4/2017	Q1 2017	$0.74	$0.75	$837.01 million	$835.60 million	View	N/A
2/7/2017	Q416	$1.06	$1.00	$842.15 million	$831.00 million	View	Listen
10/27/2016	Q316	$1.05	$1.09	$821.18 million	$828.00 million	View	Listen
7/28/2016	Q216	$1.07	$1.03	$775.68 million	$772.00 million	View	Listen
4/28/2016	Q116	$0.86	$0.87	$741.49 million	$752.60 million	View	Listen
2/4/2016	Q415	$1.10	$1.13	$748.02 million	$742.00 million	View	Listen
10/29/2015	Q315	$0.97	$1.10	$730.63 million	$722.30 million	View	Listen
7/30/2015	Q215	$0.88	$0.97	$677.02 million	$676.60 million	View	Listen
4/30/2015	Q115	$0.71	$0.72	$641.24 million	$639.40 million	View	Listen
1/29/2015	Q414	$0.87	$0.89	$637.90 million	$651.00 million	View	Listen
10/30/2014	Q314	$0.85	$0.86	$619.61 million	$627.00 million	View	Listen
7/31/2014	Q214	$0.78	$0.79	$603.00 million	$595.54 million	View	Listen
5/1/2014	Q114	$0.63	$0.63	$574.80 million	$566.00 million	View	Listen
1/30/2014	Q4	$0.75	$0.20	$555.30 million	$567.00 million	View	Listen
10/31/2013	Q313	$1.48	$1.52	$556.63 million	$555.00 million	View	Listen
7/30/2013	Q2 2013	$1.36	$1.37	$533.39 million	$529.18 million	View	Listen
5/2/2013	Q1 2013	$1.09	$1.10	$504.24 million	$502.70 million	View	Listen
1/31/2013	Q4 2012	$1.30	$1.32	$473.70 million	$471.30 million	View	Listen
11/1/2012	Q312	$1.28	$1.32	$470.60 million	$473.10 million	View	N/A
7/31/2012		$1.19	$1.22			View	N/A
5/3/2012		$1.00	$0.98			View	N/A
2/2/2012		$1.19	$1.19			View	N/A
11/1/2011		$1.18	$1.19			View	N/A
8/2/2011		$1.15	$1.15			View	N/A
5/3/2011		$0.91	$0.94			View	N/A
2/3/2011		$1.12	$1.12			View	N/A

(Data available from 1/1/2011 forward)

Earnings Estimates for Mednax (NYSE:MD)

2017 EPS Consensus Estimate: $3.58

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2017	3	$0.80	$0.81	$0.81
Q2 2017	2	$0.99	$1.00	$1.00
Q3 2017	3	$0.77	$1.07	$0.88
Q4 2017	3	$0.79	$1.09	$0.90

(Data provided by Zacks Investment Research)

Dividend History for Mednax (NYSE:MD)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading and Institutional Ownership History for Mednax (NYSE:MD)

Insider Ownership Percentage: 2.40%

Institutional Ownership by Quarter for Mednax (NYSE:MD)

Insider Trades by Quarter for Mednax (NYSE:MD)

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
9/12/2017	John C Pepia	Insider	Sell	3,000	$42.85	$128,550.00
6/14/2017	Md Pascal J Goldschmidt	Director	Sell	1,969	$57.57	$113,355.33
6/1/2017	Joseph M Calabro	Insider	Sell	23,327	$55.00	$1,282,985.00
5/5/2017	Manuel Kadre	Director	Buy	21,704	$55.79	$1,210,866.16
5/5/2017	Vivian Lopez-Blanco	CFO	Sell	7,778	$55.82	$434,167.96
2/23/2017	Enrique Sosa	Director	Sell	10,668	$69.65	$743,026.20
2/17/2017	Vivian Lopez-Blanco	CFO	Sell	15,164	$70.01	$1,061,631.64
2/16/2017	Dominic J Andreano	SVP	Sell	6,000	$69.59	$417,540.00
2/16/2017	John C Pepia	Insider	Sell	2,500	$69.58	$173,950.00
2/16/2017	Paul G Gabos	Director	Sell	21,336	$69.63	$1,485,625.68
2/10/2017	Md Pascal J Goldschmidt	Director	Sell	25,294	$67.82	$1,715,439.08
2/9/2017	Md Carlo A Waldemar	Director	Sell	5,334	$67.90	$362,178.60
1/17/2017	Vivian Lopez-Blanco	CFO	Sell	10,000	$70.95	$709,500.00
12/7/2016	Md Pascal J Goldschmidt	Director	Buy	2,100	$66.52	$139,692.00
9/14/2016	Md Pascal J Goldschmidt	Director	Sell	1,500	$65.01	$97,515.00
6/13/2016	Dominic J Andreano	SVP	Sell	3,922	$68.80	$269,833.60
6/8/2016	Md Carlo A Waldemar	Director	Sell	5,334	$70.50	$376,047.00
6/7/2016	Karl B Wagner	Insider	Sell	27,482	$68.45	$1,881,142.90
6/1/2016	Joseph M Calabro	COO	Sell	28,347	$67.78	$1,921,359.66
6/1/2016	Michael D Stanley	Insider	Sell	14,778	$67.78	$1,001,652.84
5/16/2016	Dominic J Andreano	SVP	Sell	3,000	$68.53	$205,590.00
5/2/2016	Vivian Lopez-Blanco	CFO	Sell	9,350	$71.22	$665,907.00
3/11/2016	Md Pascal J Goldschmidt	Director	Sell	3,100	$65.00	$201,500.00
2/29/2016	Paul G Gabos	Director	Sell	10,668	$67.15	$716,356.20
12/11/2015	Md Pascal J. Goldschmidt	Director	Sell	5,250	$70.99	$372,697.50
9/8/2015	Cesar L. Alvarez	Director	Sell	10,668	$81.00	$864,108.00
8/27/2015	Roger Md Medel	CEO	Sell	100,000	$80.27	$8,027,000.00
6/8/2015	Karl B Wagner	Insider	Sell	37,820	$70.28	$2,657,989.60
6/3/2015	Joseph M Calabro	COO	Sell	108,071	$70.51	$7,620,086.21
3/9/2015	Md Pascal J Goldschmidt	Director	Sell	8,500	$71.25	$605,625.00
2/26/2015	Roger Md Medel	CEO	Sell	100,000	$71.61	$7,161,000.00
2/20/2015	Md Carlo A Waldemar	Director	Sell	10,668	$71.50	$762,762.00
2/6/2015	Dominic J Andreano	SVP	Sell	3,200	$70.75	$226,400.00
2/6/2015	Vivian Lopez-Blanco	CFO	Sell	8,250	$69.95	$577,087.50
2/2/2015	Paul G Gabos	Director	Sell	17,584	$68.07	$1,196,942.88
1/30/2015	William C Hawk	COO	Sell	3,598	$68.50	$246,463.00
11/14/2014	Roger Md Medel	CEO	Sell	51,290	$62.59	$3,210,241.10
11/13/2014	Roger Md Medel	CEO	Sell	63,440	$62.55	$3,968,172.00
11/7/2014	Roger Md Medel	CEO	Sell	128,833	$62.60	$8,064,945.80
11/5/2014	Roger Md Medel	CEO	Sell	169,845	$62.60	$10,632,297.00
11/4/2014	Roger Md Medel	CEO	Sell	15,052	$62.52	$941,051.04
11/3/2014	Roger Md Medel	CEO	Sell	10,881	$62.52	$680,280.12
10/31/2014	Roger Md Medel	CEO	Sell	61,592	$62.58	$3,854,427.36
10/30/2014	Karl B Wagner	Insider	Sell	40,000	$62.50	$2,500,000.00
10/30/2014	Vivian Lopez-Blanco	CFO	Sell	8,800	$60.00	$528,000.00
7/30/2014	Karl B Wagner	Insider	Sell	80,000	$60.00	$4,800,000.00
6/10/2014	Dominic J Andreano	SVP	Sell	2,252	$58.48	$131,696.96
6/6/2014	Karl B Wagner	Insider	Sell	44,596	$58.53	$2,610,203.88
6/5/2014	William C Hawk	COO	Sell	6,911	$57.66	$398,488.26
6/2/2014	David A Clark	COO	Sell	16,230	$57.00	$925,110.00
6/2/2014	Michael D Stanley	Insider	Sell	18,006	$57.00	$1,026,342.00
5/9/2014	Karl Wagner	Insider	Sell	79,524	$57.09	$4,540,025.16
5/9/2014	Md Pascal Goldschmidt	Director	Sell	30,000	$57.11	$1,713,300.00
5/8/2014	Joseph Calabro	COO	Sell	137,500	$57.06	$7,845,750.00
2/20/2014	Dominic Andreano	SVP	Sell	3,000	$61.00	$183,000.00
2/10/2014	Joseph Calabro	COO	Sell	150,000	$55.55	$8,332,500.00
2/10/2014	Md Carlo Waldemar	Director	Sell	10,668	$55.40	$591,007.20
11/7/2013	Enrique Sosa	Director	Sell	5,334	$107.00	$570,738.00
11/7/2013	Karl Wagner	Insider	Sell	1,800	$107.60	$193,680.00
9/11/2013	William C Hawk	COO	Sell	3,162	$100.62	$318,160.44
9/10/2013	Dominic J Andreano	SVP	Sell	3,718	$99.63	$370,424.34
8/7/2013	Karl Wagner	Insider	Sell	25,000	$98.01	$2,450,250.00
8/2/2013	Joseph M Calabro	COO	Sell	36,154	$98.57	$3,563,699.78
6/3/2013	David A Clark	COO	Sell	8,645	$91.01	$786,781.45
6/3/2013	Michael D Stanley	Insider	Sell	8,906	$91.01	$810,535.06

(Data available from 1/1/2013 forward)

Headline Trends for Mednax (NYSE:MD) Latest Headlines for Mednax (NYSE:MD)

Source:

Date	Headline
	BMO Capital Markets Initiates Coverage on Mednax, Inc (MD) www.americanbankingnews.com - October 16 at 6:46 PM
	MEDNAX 2017 Third Quarter Conference Call/Webcast Scheduled for Wednesday, November 1, 2017 finance.yahoo.com - October 14 at 2:49 AM
	Research Analysts Issue Forecasts for Mednax, Inc's Q3 2017 Earnings (MD) www.americanbankingnews.com - October 11 at 6:32 AM
	MEDNAX Addresses National Opioid Use and Abuse finance.yahoo.com - October 10 at 8:09 PM
	MEDNAX, Inc. – Value Analysis (NYSE:MD) : October 6, 2017 finance.yahoo.com - October 7 at 5:04 AM
	MEDNAX, Inc. breached its 50 day moving average in a Bearish Manner : MD-US : October 5, 2017 finance.yahoo.com - October 6 at 10:18 AM
	Mednax, Inc (MD) Expected to Post Quarterly Sales of $867.78 Million www.americanbankingnews.com - October 4 at 2:54 AM
	Mednax, Inc (MD) Rating Reiterated by Jefferies Group LLC www.americanbankingnews.com - October 3 at 5:20 PM
	MEDNAX Announces Acquisition of Pediatric Urology Practice in South Florida finance.yahoo.com - October 2 at 11:59 AM
	Mednax, Inc (MD) Given Consensus Recommendation of "Hold" by Brokerages www.americanbankingnews.com - September 30 at 2:42 PM
	Comparing Mednax (MD) and Concord Medical Services Holdings Limited (CCM) www.americanbankingnews.com - September 30 at 2:42 PM
	Mednax Suffers From Low Patient Admissions, High Expenses finance.yahoo.com - September 29 at 1:41 PM
	MEDNAX Announces Acquisition of Leading Connecticut Radiology Practice - Business Wire (press release) www.businesswire.com - September 28 at 6:44 PM
	Financial Contrast: Nobilis Health Corp (HLTH) versus Mednax (MD) www.americanbankingnews.com - September 28 at 6:24 AM
	Mednax (MD) vs. China Cord Blood Corporation (CO) Financial Comparison www.americanbankingnews.com - September 23 at 2:33 PM
	Mednax (MD) vs. Laboratory Corporation of America Holdings (LH) Critical Contrast www.americanbankingnews.com - September 21 at 6:26 AM
	Mednax Stock Down 35% Year to Date: Will It Fall Further? finance.yahoo.com - September 20 at 6:11 AM
	Brokers Offer Predictions for Mednax, Inc's Q3 2017 Earnings (MD) www.americanbankingnews.com - September 19 at 7:30 AM
	Mednax, Inc (MD) Upgraded to Overweight at KeyCorp www.americanbankingnews.com - September 17 at 9:34 PM
	Stocks That Fell to Three-Year Lows in the Week of Sept. 15 www.nasdaq.com - September 17 at 7:40 PM
	Mednax, Inc (MD) Insider John C. Pepia Sells 3,000 Shares www.americanbankingnews.com - September 13 at 8:50 PM
	MEDNAX (MD) Presents At Baird's 2017 Global Healthcare Conference - Slideshow seekingalpha.com - September 8 at 3:28 AM
	Mednax, Inc (MD) Receives Average Rating of "Hold" from Brokerages www.americanbankingnews.com - September 5 at 2:40 PM
	Mednax's (MD) Hold Rating Reaffirmed at Robert W. Baird www.americanbankingnews.com - September 3 at 1:26 PM
	Mednax Becomes Oversold (MD) www.nasdaq.com - August 31 at 7:10 AM
	MEDNAX to Present at the Baird 2017 Global Healthcare Conference finance.yahoo.com - August 30 at 6:26 AM
	Pro-Trader Daily: Featured Company News - MEDNAX Acquires Leading South Florida Radiology Practice www.finanznachrichten.de - August 25 at 8:18 AM
	Featured Company News - MEDNAX Acquires Leading South Florida Radiology Practice finance.yahoo.com - August 25 at 8:18 AM
	MEDNAX Announces Acquisition of Leading South Florida Radiology Practice finance.yahoo.com - August 24 at 9:06 AM
	Mednax buys Miami practice with over 70 physicians finance.yahoo.com - August 24 at 9:06 AM
	See what the IHS Markit Score report has to say about MEDNAX Inc. finance.yahoo.com - August 16 at 6:05 AM
	ETFs with exposure to MEDNAX, Inc. : August 14, 2017 finance.yahoo.com - August 15 at 1:24 AM
	Mednax, Inc (NYSE:MD) Receives Consensus Recommendation of "Hold" from Analysts www.americanbankingnews.com - August 11 at 3:08 PM
	Head to Head Comparison: Universal Health Services (UHS) & Mednax (NYSE:MD) www.americanbankingnews.com - August 5 at 7:14 AM
	Mednax, Inc (MD) Receives Neutral Rating from Mizuho www.americanbankingnews.com - August 1 at 11:08 AM
	MEDNAX, Inc. :MD-US: Earnings Analysis: Q2, 2017 By the Numbers : July 31, 2017 finance.yahoo.com - July 31 at 8:07 PM
	MEDNAX (MD) Q2 2017 Results - Earnings Call Transcript seekingalpha.com - July 29 at 7:46 PM
	MEDNAX Reports Second Quarter GAAP EPS of $0.69 finance.yahoo.com - July 29 at 4:28 AM
	Edited Transcript of MD earnings conference call or presentation 28-Jul-17 2:00pm GMT finance.yahoo.com - July 29 at 4:28 AM
	Mednax misses Street 2Q forecasts finance.yahoo.com - July 29 at 4:28 AM
	Mednax, Inc (NYSE:MD) Issues Quarterly Earnings Results www.americanbankingnews.com - July 28 at 6:38 PM
	Why Mednax Tumbled 12% Today Despite Higher Sales www.fool.com - July 28 at 12:50 PM
	Mednax, Inc (MD) Releases Q3 Earnings Guidance www.americanbankingnews.com - July 28 at 10:23 AM
	Critical Contrast: Mednax (MD) vs. TeamHealth Holdings (TMH) www.americanbankingnews.com - July 25 at 11:02 AM
	ETFs with exposure to MEDNAX, Inc. : July 24, 2017 finance.yahoo.com - July 24 at 6:28 PM
	$851.11 Million in Sales Expected for Mednax, Inc (NYSE:MD) This Quarter www.americanbankingnews.com - July 21 at 7:35 PM
	MEDNAX, Inc. breached its 50 day moving average in a Bearish Manner : MD-US : July 20, 2017 finance.yahoo.com - July 21 at 2:10 AM
	MEDNAX 2017 Second Quarter Conference Call/Webcast Scheduled for Friday, July 28, 2017 finance.yahoo.com - July 18 at 11:14 PM
	Mednax, Inc (MD) Receives Average Recommendation of "Hold" from Brokerages www.americanbankingnews.com - July 17 at 2:50 PM
	ETFs with exposure to MEDNAX, Inc. : July 14, 2017 finance.yahoo.com - July 15 at 6:21 AM